RecruitingPhase 3NCT06930794

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Studying NLRP3-associated autoinflammatory disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Principal Investigator
Yilong Wu, MD
Guangdong Provincial People's Hospital
Intervention
Vebreltinib combined with platinum-based doublet chemotherapy.(drug)
Enrollment
300 enrolled
Eligibility
18 years · All sexes
Timeline
20252030

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06930794 on ClinicalTrials.gov

Other trials for NLRP3-associated autoinflammatory disease

Additional recruiting or active studies for the same condition.

See all trials for NLRP3-associated autoinflammatory disease

← Back to all trials